Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Pedro R. Lowenstein"'
Publikováno v:
Oncotarget
Diffuse intrinsic pontine glioma (DIPG) is a rare brainstem tumor which carries a dismal prognosis. To date. there are no effective treatments for DIPG. Transcriptomic studies have shown that DIPGs have a distinct profile compared to hemispheric high
Autor:
Kaushik Banerjee, Felipe J. Núñez, Santiago Haase, Brandon L. McClellan, Syed M. Faisal, Stephen V. Carney, Jin Yu, Mahmoud S. Alghamri, Antonela S. Asad, Alejandro J. Nicola Candia, Maria Luisa Varela, Marianela Candolfi, Pedro R. Lowenstein, Maria G. Castro
Publikováno v:
Frontiers in Molecular Neuroscience
Frontiers in Molecular Neuroscience, Vol 14 (2021)
Frontiers in Molecular Neuroscience, Vol 14 (2021)
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in the adult population and it carries a dismal prognosis. Inefficient drug delivery across the blood brain barrier (BBB), an immunosuppressive tumor microenvironment (TME) and
Autor:
Marianela Candolfi, Mahmoud S. Alghamri, David B. Altshuler, Maria G. Castro, Felipe J Nunez, Padma Kadiyala, Antonela Sofía Asad, Stephen Carney, Anna Schwendeman, Joerg Lahann, Alejandro Javier Nicola Candia, Fernando M. Nunez, Pedro R. Lowenstein, James J. Moon, Maria B. Garcia-Fabiani
Publikováno v:
Expert Opin Biol Ther
Introduction: The field of neuro-oncology has experienced significant advances in recent years. More is known now about the molecular and genetic characteristics of glioma than ever before. This knowledge leads to the understanding of glioma biology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84060f4e081cdde6482b43f3709cfb06
https://europepmc.org/articles/PMC7059118/
https://europepmc.org/articles/PMC7059118/
Autor:
Mahmoud S. Alghamri, Felipe J Nunez, Maria G. Castro, Neha Kamran, Pedro R. Lowenstein, David Altshuler, Stephen Carney
Publikováno v:
Methods Enzymol
Glioma is one of the most aggressive tumors. The median survival of the most aggressive form (Glioblastoma (GBM)) is approximately 14–20 months. The current standard of care includes tumor resection, chemotherapy and radiation, nevertheless, the in
Autor:
Meghna Saxena, Pedro R. Lowenstein, Youping Li, Maria G. Castro, Neha Kamran, Nicholas Raja, Padma Kadiyala, Diana Shah, Mariela A. Moreno-Ayala, Marianela Candolfi
Publikováno v:
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Survival of glioma (GBM) patients treated with the current standard of care remains dismal. Immunotherapeutic approaches that harness the cytotoxic and memory potential of the host immune system have shown great benefit in other cancers. GBMs have de
Autor:
Maria G. Castro, Pedro R. Lowenstein, Yohei Mineharu, Gregory J. Baker, Anda Alexandra Calinescu, Neha Kamran
Publikováno v:
Immunotherapy. 7:1073-1104
In the last decade, numerous studies of immunotherapy for malignant glioma (glioblastoma multiforme) have brought new knowledge and new hope for improving the prognosis of this incurable disease. Some clinical trials have reached Phase III, following
Autor:
Pedro R. Lowenstein, Diana Shah, Carl Koschmann, Mayuri Chandran, Antonela Sofía Asad, Maria G. Castro, Yohei Mineharu, Viveka Nand Yadav, Marianela Candolfi
Publikováno v:
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Introduction: Malignant gliomas are highly invasive tumors, associated with a dismal survival rate despite standard of care, which includes surgical resection, radiotherapy and chemotherapy with temozolomide (TMZ). Precision immunotherapies or combin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f12dd2baa5a047ee9c7156f7bfac1e7
https://www.tandfonline.com/doi/full/10.1080/14712598.2017.1305353
https://www.tandfonline.com/doi/full/10.1080/14712598.2017.1305353
Autor:
Mariela A. Moreno Ayala, Marianela Candolfi, Neha Kamran, Pedro R. Lowenstein, Marta Dzaman, Gregory J. Baker, Maria G. Castro
Publikováno v:
Gene Therapy for Neurological Disorders : Methods and Protocols
Gene Therapy for Neurological Disorders ISBN: 9781493932702
Gene Therapy for Neurological Disorders ISBN: 9781493932702
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults with a median survival of 16.2–21.2 months post diagnosis (Stupp et al., N Engl J Med 352(10): 987–996, 2005). Because of its location, complete surgical resection is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78ffa175e24e22a70f812f6a4ad09734
https://link.springer.com/protocol/10.1007/978-1-4939-3271-9_31
https://link.springer.com/protocol/10.1007/978-1-4939-3271-9_31
Autor:
Marianela Candolfi, Hikmat Assi, Mariela A. Moreno-Ayala, Alexandra Calinescu, Carl Koschmann, Neha Kamran, Christopher Paran, Pedro R. Lowenstein, Thomas J. Wilson, Maria G. Castro
Publikováno v:
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
INTRODUCTION: Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults and it carries a dismal prognosis. Adenoviral vector (Ad)-mediated gene transfer is being developed as a promising therapeutic strategy for GBM. Preclinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e617accb928337da1cdc7c4e98063a93
http://www.tandfonline.com/doi/full/10.1517/14712598.2014.915307
http://www.tandfonline.com/doi/full/10.1517/14712598.2014.915307
Autor:
Hikmat Assi, Pedro R. Lowenstein, David Foulad, Maria G. Castro, Yohei Mineharu, Mia Wibowo, Gwendalyn D. King, Marianela Candolfi, James F. Curtin, Kurt M. Kroeger, Mariana Puntel, A.K.M. Ghulam Muhammad, Kader Yagiz
Publikováno v:
Current Gene Therapy. 5:535-557
The most common primary brain tumor in adults is glioblastoma. These tumors are highly invasive and aggressive with a mean survival time of nine to twelve months from diagnosis to death. Current treatment modalities are unable to significantly prolon